Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer-status of the art

Critical Reviews in Oncology/Hematology

Volumn 30, Issue 1, 1999, Pages 71-79

  Gamelin, Erick ^a   Boisdron Celle, Michele ^a  

^a CENTRE PAUL PAPIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; INTERFERON; THYMIDYLATE SYNTHASE;

AREA UNDER THE CURVE; BOLUS INJECTION; CEREBELLUM DISEASE; COLORECTAL CANCER; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME DEFICIENCY; EPILEPSY; FAMILIAL DISEASE; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAXIMUM PERMISSIBLE DOSE; MENTAL DEFICIENCY; MUCOSA INFLAMMATION; NEUROTOXICITY; REVIEW; STEADY STATE; STOMATITIS;

EID: 0033015578     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(98)00036-5     Document Type: Article

References (55)

1. Vokes E.E., Weichselbaum R.R., Lippman S. et al. Head and neck cancer. N. Engl. J. Med. 328:1993;184-194.
2. Bruckner H.W., Motwani B.T. Chemotherapy of advanced cancer of the colon and rectum. Semin. Oncol. 18:1991;443-461.
3. Machover D., Goldschmidt E., Chollet P. et al. Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high-dose folinic acid. J. Clin. Oncol. 4:1986;685-696.
4. Poon M.A., O'Connell M.J., Wieand H.S. et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved efficacy in advanced colorectal cancer. J. Clin. Oncol. 9:1991;1967-1972.
5. Stupp R., Weichselbaum R.R., Vokes E.E. Combined modality therapy of head and neck cancer. Semin. Oncol. 21:1994;349-358.
6. Vokes E.E., Choi K.E., Schilsky R.L. et al. Cisplatin, fluorouracil and high-dose leucovorin for recurrent or metastatic head and neck cancer. J. Clin. Oncol. 6:1988;618-626.
7. Dreyfuss A.I., Clark J.R., Wright J.E. et al. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. An. Intern. Med. 112:1990;167-172.
8. Pfister D.G., Bajorin D., Motzer R. et al. Cisplatin, fluorouracil and leucovorin: increased toxicity without improved response in squamous cell head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 120:1994;89-95.
9. Arbuck S.G. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer. 63:1989;1036-1044.
10. Hull W.E., Port R.E., Herrmann R. et al. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res. 48:1988;1680-1688.
11. Mc Dermott B.J., Van den Berg H.W., Murphy R.F. Non-linear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Cancer Chemother. Pharmacol. 9:1982;173-178.
12. Pinedo H.M., Peters G.F.J. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 6:1988;1653-1664.
13. Trump D.L., Egorin M.J., Forrest A. et al. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72 hour continuous infusion with and without dipyridamole. J. Clin. Oncol. 9:1991;2027-2035.
14. Wagner J.G., Gyves J.W., Stetson P.L. et al. Steady state non-linear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res. 46:1986;1499-1506.
15. Brohee D. 5-fluorouracil with or without folinic acid in human colorectal cancer? multivariate metaanalysis of the literature. Med. Oncol. Tumor. Pharmacother. 8:1991;271-280.
16. Hryniuk W.M., Figueredo A., Goodyear M. Applications of dose-intensity to problems in chemotherapy of breast and colorectal cancer. Semin. Oncol. 14:1987;3-11.
17. Spicer D.V., Ardalan B., Daniels J.R. et al. Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res. 48:1988;459-461.
18. Erlichman C., Fine S., Elhakim T. Plasma pharmacokinetic of 5-FU given by continuous infusion with allopurinol. Cancer Treat. Rep. 70:1986;903-904.
19. Ratain M.J., Schilsky R.L.R., Conley B.A. et al. Pharmacodynamics in cancer therapy. J. Clin. Oncol. 8:1990;1739-1753.
20. Milano G., Roman P., Khater P. et al. Dose versus pharmacokinetics for predicting tolerance to 5 day continuous infusion of 5-FU. Int. J. Cancer. 41:1988;537-541.
21. Thyss A., Milano G., Renee N. et al. Clinical pharmacokinetic study of 5-FU in continuous 5 day infusions for head and neck cancer. Cancer Chemother. Pharmacol. 16:1986;64-66.
22. Santini J., Milano G., Thyss A. et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br. J. Cancer. 59:1989;287-290.
23. Milano G., Etienne M.C., Renee N. et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J. Clin. Oncol. 12:1994;1291-1295.
24. Sobrero A.F., Aschele C., Bertino J.R. Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J. Clin. Oncol. 15:1997;368-381.
25. Parker W.B., Cheng Y.C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Ther. 48:1990;381-395.
26. Gamelin E.C., Danquechin-Dorval E.M., Dumesnily et al. Relationship between 5-fluorouracil dose-intensity and therapeutic response in patients with advanced colorectal cancer receiving 5-FU containing infusional therapy. Cancer 1996;77:441-451.
27. Yoshida T., Araki E., Ligo M. et al. Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother. Pharmacol. 26:1990;352-354.
28. Au J.L.S., Rustum Y.M., Lederma E.J. et al. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in the treatment of colorectal carcinoma. Cancer Res. 42:1982;2903-2937.
29. Van-Groeningen C.J., Pinedo H.M., Heddes J. et al. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res. 48:1988;6956-6961.
30. Schneider M., Etienne M.C., Milano G. et al. Phase II trial of cisplatin, fluorouracil and pure folinic acid for locally advanced head and neck cancer a pharmacokinetic and clinical survey. J. Clin. Oncol. 13:1995;1656-1662.
31. Vokes E.E., Mick R., Kies M.S. et al. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J. Clin. Oncol. 14:1996;1663-1671.
32. Hillcoat B.L., Mc Culloch P.B., Figueredo A.T. et al. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br. J. Cancer. 38:1978;719-724.
33. Seitz J.F., Cano J.P., Rigault J.P. et al. Chimiothérapie des cancers digestifs étendus par le 5-Fluorouracile: relations entre la réponse clinique et la clairance plasmatique du médicament. Gastroenterol. Clin. Biol. 7:1983;374-380.
34. Etienne M.C., Lagrange J.L., Dassonville O. et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12:1994;2248-2253.
35. Lu Z., Zhang R., Diasio R.B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in fluorouracil chemotherapy. Cancer Res. 53:1993;5433-5438.
36. Harris B.E., Carpenter J.T., Diasio R.B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer. 68:1991;499-501.
37. Tuchman M., Stoeckler J.S., Kiang D.T. et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. New Engl. J. Médecine. 313:1985;245-249.
38. Diasio R.B., Beavers T.L., Carpenter J.T. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest. 81:1988;47-51.
39. Lu Z., Zhang R., Carpenter J.T., Diasio R.B. Decreased dihydropyrimidine dehydrogenase activity in a population of patents with breast cancer: implications for 5-fluororucil-based chemotherapy. Clin. Cancer Res. 4:1998;325-329.
40. Milano G., Etienne M.C., Cassuto-Viguier E. et al. Influence of sex and age on fluorouracil clearance. J. Clin. Oncol. 10:1992;1171-1175.
41. Fleming R., Milano G., Thyss A. et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 52:1992;2899-2902.
42. Harris B.E., Song R., Soong S.J., Diasio R.B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50:1990;197-201.
43. Stephan F., Etienne M.C., Wallays C., Milano G., Clergue F. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am. J. Med. 99:1995;685-688.
44. Van Gennip A.H., Van Bree-Blom E.J., Wadman S.K. et al. HPLC of urinary pyrimidines for the evaluation of primary and secondary abnormalities of pyrimidine metabolism. Hawk G.L. Biological Biomedical Applications of Liquid Chromatography III. 1982;285-296 Marcel Dekker, New York and Basel.
45. Bakkeren J.A.J.M., De Abreu R.A., Sengers R.C.A. et al. Elevated urine and cerebrospinal fluid levels of uracil and thymine in a child with dihydrothymine dehydrogenase deficiency. Clin. Chim. Acta. 140:1984;247-256.
46. Sumi S., Kidouchi K., Ohba S. et al. Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography. J. Chromatogr. 672:1990;233-239.
47. Gamelin E., Boisdron-Celle M., Larra F. et al. A simple chromatographic method for the analysis of pyrimidines and their dihydrogenated metabolites. J. Liq. Chromatogr. Rel. Technol. 20:1997;3155-3172.
48. Etienne M. C., Cheradame S., Fischel J.L. et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J. Clin. Oncol. 13:1995;1663-1670.
49. Fety R., Rolland F., Barberi-Heyob M. et al. Clinical randomized study of 5-FU monitoring versus standard dose in patients with head and neck cancer: preliminary results. Anticancer Res. 14:1994;2347-2352.
50. Etienne M.C., Chatelut E., Pivot X. et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion: a NONMEM analysis. Eur. J. Cancer. 34:1998;92-97.
51. Gamelin E., Boisdron-Celle M., Delva R. et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J. Clin. Oncol. 16:1998;1470-1478.
52. Troncale F., Hertz R., Lipkin M. Nucleic acid metabolism in proliferating and differentiating colonic cells of man and in neoplastic lesions of the colon. Cancer Res. 31:1971;463-467.
53. Ardalan B., Chua L., Tian E. et al. A phase II study of weekly 24 hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J. Clin. Oncol. 9:1991;625-630.
54. Diaz-Rubio E., Aranda E., Martin M. et al. Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur. J. Cancer. 26:1990;727-729.
55. Wils J.A. High-dose fluorouracil: a new perspective in the treatment of colorectal cancer? Semin. Oncol. 19(Suppl 3):1992;126-130.